Ionis Pharmaceuticals Inc.

Compare

1,447 Followers

IONS Stock Chart & Stats

$74.30

-$0.75(-2.14%)

At close: Jan 08 4:00 PM EST

$74.30

-$0.75(-2.14%)

Day’s Range― - ―

52-Week Range$23.95 - $75.49

Previous CloseN/A

Volume126.35K

Average Volume (3M)2.08M

Market Cap

$12.03B

Enterprise Value$10.26B

Total Cash (Recent Filing)$2.24B

Total Debt (Recent Filing)$2.01B

Price to Earnings (P/E)―

Beta0.81

Next Earnings

Feb 25, 2026

EPS Estimate

-1.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.80

Shares Outstanding161,974,400

10 Day Avg. Volume2,006,346

30 Day Avg. Volume2,076,622

Financial Highlights & Ratios

PEG Ratio-0.61

Price to Book (P/B)8.88

Price to Sales (P/S)7.41

P/FCF Ratio-9.57

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue10.61

Enterprise Value/Gross Profit10.74

Enterprise Value/Ebitda-63.08

Forecast

1Y Price Target

$80.80

Price Target Upside8.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering21

Bulls Say, Bears Say

Bulls Say

Market Growth PotentialThe olezarsen market is perceived to be much larger than previously advertised, indicating a substantial growth opportunity.

Product PerformanceTryngolza sales of $32M were notably above expectations highlighting continued strong trends/execution for first independent launch.

Revenue GrowthThe company raised FY25 sales guidance to $85-95M, indicating continued favorable trends.

Bears Say

Ionis Pharmaceuticals News

Ionis Pharmaceuticals price target raised to $100 from $95 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $100 from $95 and keeps a...

4d ago

IONS

Ionis Pharmaceuticals price target raised to $94 from $90 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $94 from $90 and keeps an...

4d ago

IONS

Ionis Pharmaceuticals price target raised to $99 from $59 at TD Cowen

TD Cowen raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $99 from $59 and keeps a...

4d ago

IONS

Ionis Pharmaceuticals price target raised to $95 from $80 at Barclays

Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $80 and keeps an Overweight...

4d ago

IONS

Ionis Pharmaceuticals raises FY25 revenue view to $875M-$900M from $825M-$850M

Consensus $866.53M. The company said, “Increasing 2025 financial guidance reflects strong overall revenue performance experienced year-to-date and fourth...

5d ago

IONS

Ionis Pharmaceuticals reports Q3 EPS (80c), consensus ($1.05)

Reports Q3 revenue $157M, consensus $130.51M. “The third quarter was a watershed moment for Ionis, as we made...

5d ago

IONS

AMZN, BABA, NTLA, XYZ: Cathie Wood Loads Up on Intellia, Block, Amazon & Alibaba, Cuts Stake in Shopify and Other Growth Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Monday, October 27, 2025, signaling stronger conviction in...

6d ago

XYZ

AMZN

Ionis Pharmaceuticals price target raised to $90 from $86 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $86 and keeps an...

18d ago

IONS

Intel, FedEx downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

26d ago

CEG

Ionis Pharmaceuticals price target raised to $90 from $84 at Oppenheimer

Oppenheimer analyst Justin Kim raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $90 from $84 and...

26d ago

IONS

Ionis Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan

JPMorgan analyst Jessica Fye upgraded Ionis Pharmaceuticals (IONS) to Overweight from Neutral with a price target of $80,...

26d ago

IONS

Ionis Pharmaceuticals Faces Investor Risks Amid Market Volatility and Milestone Uncertainties

Ionis Pharmaceuticals Inc. (IONS) has disclosed a new risk, in the Debt & Financing category. Ionis Pharmaceuticals Inc....

3d ago

IONS

Ionis Pharmaceuticals: Strong Q3 Performance and Promising Future Catalysts Support Buy Rating

In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Ionis Pharmaceuticals, with...

4d ago

IONS

Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Ionis Pharmaceuticals. The associated...

4d ago

IONS

IONS FAQ

What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?

Ionis Pharmaceuticals Inc. lowest stock price was $23.95 and its highest was $75.49 in the past 12 months.

What is Ionis Pharmaceuticals Inc.’s market cap?

Ionis Pharmaceuticals Inc.’s market cap is $12.03B.

When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?

Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Feb 25, 2026 which is in 114 days.

How were Ionis Pharmaceuticals Inc.’s earnings last quarter?

Ionis Pharmaceuticals Inc. released its earnings results on Oct 29, 2025. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.418.

Is Ionis Pharmaceuticals Inc. overvalued?

According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ionis Pharmaceuticals Inc. pay dividends?

Ionis Pharmaceuticals Inc. does not currently pay dividends.

What is Ionis Pharmaceuticals Inc.’s EPS estimate?

Ionis Pharmaceuticals Inc.’s EPS estimate is -1.35.

How many shares outstanding does Ionis Pharmaceuticals Inc. have?

Ionis Pharmaceuticals Inc. has 161,974,400 shares outstanding.

What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?

Ionis Pharmaceuticals Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went down -2.297%.

Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?

Currently, no hedge funds are holding shares in IONS

Ionis Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-39.99%

Trailing 12-Months

Asset Growth

-1.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Carlsbad, California, specializing in the development of innovative RNA-targeted therapies. The company focuses on treating a range of diseases, including neurological disorders, cardiovascular diseases, and metabolic conditions, with a robust pipeline of drug candidates that leverage its proprietary antisense technology. Ionis collaborates with various pharmaceutical companies to enhance drug development and expand its therapeutic reach.

Ionis Pharmaceuticals (IONS) Earnings & Revenues

Historic Earnings Reports

IONS Company Deck

IONS Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Ionis Pharmaceuticals demonstrated strong revenue growth and successful product launches, with significant advancements in their clinical pipeline. Despite these achievements, the company faces challenges with operating losses and patient identification for Tringolza. Overall, the positive developments outweigh the challenges.View all IONS earnings summaries

IONS Revenue Breakdown

60.82% R&D

39.18% Commercial

IONS Stock 12 Month Forecast

Average Price Target

$80.80

▲(8.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","101":"$101","44.75":"$44.8","63.5":"$63.5","82.25":"$82.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$80.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,44.75,63.5,82.25,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.8,68.43076923076923,71.06153846153846,73.6923076923077,76.32307692307693,78.95384615384616,81.58461538461539,84.21538461538461,86.84615384615384,89.47692307692307,92.1076923076923,94.73846153846154,97.36923076923077,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.8,66.95384615384616,68.1076923076923,69.26153846153846,70.41538461538461,71.56923076923077,72.72307692307692,73.87692307692308,75.03076923076922,76.18461538461538,77.33846153846153,78.49230769230769,79.64615384615384,{"y":80.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,65.8,64.27692307692307,62.753846153846155,61.230769230769226,59.707692307692305,58.184615384615384,56.66153846153846,55.13846153846154,53.61538461538461,52.09230769230769,50.56923076923077,49.04615384615384,47.52307692307693,{"y":46,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 66,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >